Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability

Table 3

Physical parameters of the optimized formulation (F3) when stored at 25°C (RT) and (4°C) for a period of 2 months.

Day	At room temperature				At refrigerated temperature
	Size (nm)*	PDI	Zeta potential (mV)	EE (%)	Size (nm)*	PDI	Zeta potential (mV)	EE (%)
1	174.73±4.49	0.305±0.09	−28.1±2.16	91.5±0.30	174.73±4.7	0.305±0.09	−28.1±2.16	91.5±0.30
30	205.56±8.58	0.309±0.14	−26.3±2.06	87.2±0.24	194.23±2.8	0.310±0.01	−26.1±2.04	89.6±0.42
60	210.9±11.49	0.308±0.06	−26.4±2.08	82.1±0.34	200.0±8.5	0.311±0.03	−26.6±2.12	85.4±0.18

The statistical comparison of data was done using unpaired 𝑡-test by GraphPad Prism software (version 5.0, 2007), and significance was calculated at 𝑃 value of 0.05. *Significant difference was observed related to size of the SLN (𝑃=0.63). No significant difference was observed related to PDI, zeta potential, and EE during 1st, 30th and 60th day of storage.